Merck & Co., Inc. (MRK) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 66.57B USD | |
| Cost of products and services | 18.00B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $66.57B | $18.00B | (m) |
| 2026-03-31 | (m) | $65.77B | $17.16B | (m) |
| 2025-12-31 | (m) | $65.01B | $16.38B | (m) |
| 2025-09-30 | (m) | $64.23B | $14.66B | (m) |
| 2025-06-30 | (m) | $63.62B | $14.88B | (m) |
| 2025-03-31 | (m) | $63.92B | $15.07B | (m) |
| 2024-12-31 | (m) | $64.17B | $15.19B | (m) |
| 2024-09-30 | (m) | $63.17B | $15.28B | (m) |
| 2024-06-30 | (m) | $62.48B | $15.46B | (m) |
| 2024-03-31 | (m) | $61.40B | $15.74B | (m) |
| 2023-12-31 | (m) | $60.12B | $16.13B | (m) |
| 2023-09-30 | (m) | $59.31B | $16.09B | (m) |
| 2023-06-30 | (m) | $58.31B | $15.77B | (m) |
| 2023-03-31 | (m) | $57.87B | $15.96B | (m) |
| 2022-12-31 | (m) | $59.28B | $17.41B | (m) |
| 2022-09-30 | (m) | $58.97B | $17.40B | (m) |
| 2022-06-30 | (m) | $57.17B | $16.92B | (m) |
| 2022-03-31 | (m) | $53.98B | $15.81B | (m) |
| 2021-12-31 | (m) | $48.70B | $13.63B | (m) |
| 2021-09-30 | (m) | $52.61B | $16.65B | (m) |
| 2021-06-30 | (m) | $50.38B | $16.21B | (m) |
| 2021-03-31 | (m) | $48.02B | $15.84B | (m) |
| 2020-12-31 | (m) | $47.99B | $15.48B | (m) |
| 2020-09-30 | (m) | $47.35B | $13.62B | (m) |
| 2020-06-30 | (m) | $47.19B | $14.13B | (m) |
| 2020-03-31 | (m) | $48.08B | $14.37B | (m) |
| 2019-12-31 | (m) | $46.84B | $14.11B | (m) |
| 2019-09-30 | (m) | $45.97B | $13.73B | (m) |
| 2019-06-30 | (m) | $44.37B | $13.36B | (m) |
| 2019-03-31 | (m) | $43.07B | $13.38B | (m) |
| 2018-12-31 | (m) | $42.29B | $13.51B | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $40.12B | $12.91B | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $39.81B | $14.03B | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $45.99B | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | $33.47B | (m) | (m) |
| 2009-12-31 | (m) | $27.43B | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $23.85B | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $24.20B | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |